NA
TEVA icon

Nautilus Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Nautilus Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,625
Closed -$207K – 175
2025
Q4 		$207K Sell
6,625
-5,300
-44% -$131K 0.14% 168
2025
Q3 		$241K Hold
11,925
– – 0.16% 149
2025
Q2 		$200K Hold
11,925
– – 0.15% 162
2025
Q1 		$183K Hold
11,925
– – 0.15% 153
2024
Q4 		$263K Buy
+11,925
New +$217K 0.21% 126

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nautilus Advisors's TEVA Position: Q1 2026 in Review

Nautilus Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 6,625 shares — an estimated $207K sold.

Nautilus Advisors first reported a position in TEVA in Q4 2024 and held it in 5 quarters. The position peaked at $263K in Q4 2024. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Nautilus Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nautilus Advisors sold 6,625 Teva Pharmaceuticals shares in Q1 2026, an estimated $207K.
  • Nautilus Advisors first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Nautilus Advisors's Teva Pharmaceuticals position peaked at $263K in Q4 2024.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Nautilus Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.